Want to see SRXH full AI Analyst Report?
Top Page
SRx Health Solutions
(NYSE MKT:SRXH)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▲(733.33% Upside)
Action:Reiterated
Date:07/15/26
SRXH scores low primarily due to weak financial performance (recurring losses and negative cash generation) and a strongly bearish technical setup with price far below key moving averages. Valuation is constrained by loss-making results (negative P/E), while corporate events provide only partial offset: shareholder-return actions are positive, but they are accompanied by listing-compliance-driven restructuring and a high-uncertainty strategic pivot.
Positive Factors
Strategic pivot to digital assets and AI
The completed acquisition and rebrand create a structurally different business model: an AI-enabled capital allocation platform plus digital-asset operations. This diversification can generate recurring treasury income, broaden addressable markets beyond specialty pharmacy, and create multiple long-term revenue streams.
Negative Factors
Persistent negative cash generation
Sustained negative operating cash flow and intermittent free cash flow mean core operations do not reliably self-fund. Over a multi-month horizon this forces dependence on asset sales, treasury returns, or external financing, reducing strategic flexibility and increasing execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic pivot to digital assets and AI
The completed acquisition and rebrand create a structurally different business model: an AI-enabled capital allocation platform plus digital-asset operations. This diversification can generate recurring treasury income, broaden addressable markets beyond specialty pharmacy, and create multiple long-term revenue streams.
Read all positive factors
SRx Health Solutions (SRXH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.09M
Dividend YieldN/A
Average Volume (3M)6.88M
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees11
SectorConsumer Defensive
Sector Strength42
IndustrySoftware - Application
Share Statistics
EPS (TTM)-123.08
Shares Outstanding19,517,834
10 Day Avg. Volume18,039,485
30 Day Avg. Volume6,882,557
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)22.88
Price to Sales (P/S)1.43
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.20
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-1.08
Enterprise Value/Ebitda-0.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.32
Revenue Forecast (FY)$95.00M
SRx Health Solutions Business Overview & Revenue Model
Company Description
SRX Global Inc. develops artificial intelligence (AI)-powered solutions designed to improve decision-making, streamline operations, and strengthen risk management. The company is headquartered in Tampa, Florida....
How the Company Makes Money
SRx Health Solutions primarily makes money through specialty pharmacy operations: (1) dispensing specialty medications and earning reimbursement from payors (public and private insurers) for the drug product and associated pharmacy services; reven...
SRx Health Solutions Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 20, 2027
Earnings Call Sentiment Positive
The earnings call highlighted significant improvements in profitability measures, including gross profit margins, net loss, and EBITDA. Revenue growth, particularly in the fourth quarter and international markets, was strong. However, there were challenges such as a decline in annual net revenues and ongoing EBITDA losses. Overall, the company's strategic pivots and financial health improvements contributed to a positive outlook.Positive Updates
Improved Gross Profit Margin
The company reported a gross profit margin of 37% for the full year, representing an increase of over 600 basis points.
Negative Updates
Decline in Annual Net Revenues
Annual net revenues were down 9% due to strategic exits from non-core sales channels and the closure of an unprofitable direct-to-consumer business.
Read all updates
Q4-2024 Updates
Positive
Negative
Improved Gross Profit Margin
The company reported a gross profit margin of 37% for the full year, representing an increase of over 600 basis points.
Read all positive updates
Company Guidance
In the fourth quarter of 2024, Better Choice Company reported notable financial achievements and strategic advancements. The company delivered a gross profit margin of 37%, improving by over 600 basis points year-over-year, and adjusted EBITDA loss was reduced by 78% to approximately $1.9 million on annual net revenues of $35 million. The company experienced a 26% increase in fourth-quarter revenue, driven by 32% growth on platforms like Amazon and Chewy, and 18% international growth. Key operational improvements included a 22% reduction in SG&A expenses and a more than 40% reduction in inventory, leading to a working capital position of $7.9 million. Additionally, Better Choice successfully negotiated a $6.2 million gain from extinguishing debt and accounts payable. The company's focus on e-commerce channels is expected to continue propelling growth into 2025, as evidenced by the profitability improvements and strategic exits from non-core sales channels. Looking forward, Better Choice is poised for expanded growth through its acquisition of SRx Health Solutions, which is anticipated to close in April, further solidifying its position as a leader in the pet health and wellness sector.SRx Health Solutions Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
31
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Sep 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -30.49M | 6.53M | 50.30M | 118.94M | 92.63M | 58.63M |
| Gross Profit | -8.21M | 1.53M | 18.49M | 23.61M | 13.31M | 17.47M |
| EBITDA | -17.44M | -7.98M | 629.88K | -7.05M | -539.40K | 10.58M |
| Net Income | -51.41M | -45.01M | -241.60K | -11.14M | -2.45M | 3.80M |
Balance Sheet | ||||||
| Total Assets | 43.36M | 8.40M | 22.72M | 64.51M | 34.79M | 98.67M |
| Cash, Cash Equivalents and Short-Term Investments | 26.07M | 1.31M | 6.41M | 2.07M | 1.66M | 36.89M |
| Total Debt | 22.62M | 4.47M | 2.02M | 39.38M | 17.85M | 13.16M |
| Total Liabilities | 25.08M | 8.00M | 120.62M | 70.80M | 33.86M | 24.91M |
| Stockholders Equity | 18.29M | 407.00K | 13.91M | 15.08M | 45.38M | 73.76M |
Cash Flow | ||||||
| Free Cash Flow | -20.52M | -8.14M | -5.97M | 1.58M | 4.33M | -15.56M |
| Operating Cash Flow | -12.07M | -8.14M | -5.91M | 2.85M | -27.62M | -15.11M |
| Investing Cash Flow | -11.37M | 5.91M | -3.06M | -19.78M | -266.04K | -449.89K |
| Financing Cash Flow | 57.63M | 12.17M | 7.08M | 16.43M | 1.72M | 47.36M |
SRx Health Solutions Technical Analysis
Negative
0.24
Price Trends
6.34
Negative
6.97
Negative
11.50
Negative
Market Momentum
-1.38
Positive
34.94
Neutral
27.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRXH, the sentiment is Negative. The current price of 0.24 is below the 20-day moving average (MA) of 4.47, below the 50-day MA of 6.34, and below the 200-day MA of 11.50, indicating a bearish trend. The MACD of -1.38 indicates Positive momentum. The RSI at 34.94 is Neutral, neither overbought nor oversold. The STOCH value of 27.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRXH.
SRx Health Solutions Risk Analysis
SRx Health Solutions disclosed 96 risk factors in its most recent earnings report. SRx Health Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SRx Health Solutions Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $3.54B | 14.20 | 29.87% | 4.80% | -2.08% | -67.52% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | $6.21B | 14.97 | 7.88% | 1.56% | 8.91% | 129.84% | |
45 Neutral | $64.05M | -1.45 | -99.47% | ― | ― | ― | |
42 Neutral | $45.09M | ― | 875.03% | ― | ― | ― |
* Consumer Defensive Sector Average
SRXH
SRx Health Solutions
2.41
-30.84
-92.75%
GRFS
Grifols SA
7.33
-2.48
-25.26%
SCLX
Scilex Holding Company
8.79
3.03
52.63%
OGN
Organon
13.49
3.94
41.18%
CTOR
Citius Oncology
0.68
-0.92
-57.38%
MIRA
MIRA Pharmaceuticals, Inc.
0.93
-1.09
-53.81%
SRx Health Solutions Corporate Events
Business Operations and StrategyStock BuybackDividendsFinancial DisclosuresM&A TransactionsStock Split
SRx Health Announces One-Time Dividend and Share Buyback
Positive
Jul 10, 2026
On July 8, 2026, SRX Global Inc. declared a one-time cash dividend of $0.05 per share, totaling approximately $1 million, payable on or about August 3, 2026 to shareholders of record as of July 22. The payout is funded by profits from the company&...
Business Operations and StrategyRegulatory Filings and Compliance
SRx Health Issues New Investor Presentation With Cautions
Neutral
Jun 26, 2026
On June 26, 2026, SRX Global Inc. posted a new investor presentation on its website and furnished it as an exhibit to a current report, indicating it plans to use the materials in ongoing meetings with investors and analysts. The company emphasize...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
SRx Health Announces 60-for-1 Share Consolidation Plan
Negative
Jun 24, 2026
On March 23, 2026, SRX Global was notified by NYSE American that it was out of compliance with continued listing standards after its stock traded at a low price for an extended period and closed below $0.10 on June 23, 2026. NYSE American halted t...
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
SRx Health Rebrands, Completes Crypto Share Exchange Pivot
Positive
Jun 18, 2026
On June 18, 2026, SRx Health Solutions completed its previously announced share exchange transaction with EMJ Crypto Technologies and CCC Crypto, acquiring full ownership of both entities and associated IP assets. In exchange, the company issued h...
Business Operations and StrategyM&A Transactions
SRx Health Shifts Capital Toward AI and Space Investments
Positive
Apr 22, 2026
On April 22, 2026, SRx Health Solutions announced that its wholly owned pet-focused subsidiary, Halo, Purely for Pets, invested more than 10% of the company’s investable capital in Astro Investment XVII, an affiliate of Astro Capital structu...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
SRx Health Updates Shareholders on EMJX Merger Progress
Positive
Apr 17, 2026
On April 17, 2026, SRx Health Solutions and EMJ Crypto Technologies released a shareholder letter detailing operational progress and the status of their proposed merger, which was first announced in December 2025. EMJX highlighted strong early per...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.